Your browser is no longer supported. Please, upgrade your browser.
Order: Signal: Tickers:
Overview Valuation Financial Ownership Performance Technical Custom Charts Tickers Quotes Basic TA News Snapshot Stats
Total: 65 #1
IndustryMovie Production, Theaters
Market Cap6.22MEPS (ttm)-0.30
P/E-EPS this Y-
Forward P/E-EPS next Y-
PEG-EPS past 5Y0.00%
P/S0.28EPS next 5Y-
P/B1.47EPS Q/Q-
Dividend-Sales Q/Q-13.20%
Insider Own62.42%Inst Own3.80%
Insider Trans-Inst Trans-25.21%
Short Float1.46%EarningsAug 13/b
Analyst Recom-Target Price-
Avg Volume14.18K52W Range0.40 - 0.59
Jul-14-15 03:00PMPOINT.360 Files SEC form 8-K, Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of
Jul-09-15 01:30PMPoint.360 Acquires The Assets Of Modern VideoFilm PR Newswire
May-22-15 05:00PMPoint.360 To Acquire Modern VideoFilm PR Newswire
May-22-15 01:04PMPOINT.360 Financials
May-14-15 09:01AMPOINT.360 Files SEC form 8-K, Results of Operations and Financial Condition
May-14-15 09:00AMPoint.360 Announces Third Fiscal Quarter And Nine Month Results PR Newswire
May-14-15 07:45AMPoint.360 Invites You to Join Its Third Quarter Conference Call PR Newswire
May-08-15 12:20PMPoint.360 Invites You to Join Its Third Quarter Conference Call PR Newswire
Mar-04-15 12:53PMPOINT.360 Files SEC form 8-K, Termination of a Material Definitive Agreement
Feb-19-15 09:00AMPoint.360 Announces New Financing PR Newswire
Point.360 operates as an integrated media management services company in the United States. It offers film, video and audio post-production, archival, duplication, and data distribution services. The company also provides services to edit, master, reformat, convert, archive, and distribute its clients' audio, video, and film content, including television programming, feature films, and movie trailers. Its value-added services comprise digital and video editing, digital color correction, picture restoration, audio post-production, audio restoration and layback, closed captioning and subtitling, foreign language mastering, standards conversion, broadcast encoding, global distribution and syndication, and archival services. In addition, Point.360 is involved in the rental and sale of DVDs and video games to consumers through its Movie>Q retail stores. Its customers include independent motion picture and television studios, cable television program suppliers, and television program syndicators, as well as national television networks, local television stations, corporate or instructional video providers, and educational institutions. The company is based in Los Angeles, California.
CompanyProgenics Pharmaceuticals, Inc.
Market Cap635.81MEPS (ttm)0.06
P/E152.17EPS this Y107.90%
Forward P/E913.00EPS next Y102.00%
PEG6.09EPS past 5Y15.60%
P/S14.86EPS next 5Y25.00%
P/B5.50EPS Q/Q0.00%
Dividend-Sales Q/Q-88.90%
Insider Own0.10%Inst Own94.40%
Insider Trans-14.70%Inst Trans0.16%
Short Float17.79%EarningsAug 06/b
Analyst Recom1.80Target Price9.50
Avg Volume1.35M52W Range4.26 - 9.75
Jul-28-15 12:43PMTrending Now: PGNX
Jul-28-15 11:24AMWhy Progenics Pharmaceuticals' Stock Bolted Higher Today at Motley Fool
Jul-28-15 10:37AMMid-Morning Market Update: Markets Rise; Ford Beats Q2 Estimates
Jul-28-15 08:31AM8:31 am Progenics Pharm announces US FDA Breakthrough Therapy designation for Azedra, to treat iobenguane-avid metastatic or recurrent pheochromocytoma and paraganglioma
Jul-28-15 08:30AMProgenics Announces Breakthrough Therapy Designation for Azedra in Pheochromocytoma and Paraganglioma GlobeNewswire
Jul-22-15 09:24AMProgenics (PGNX) Shares March Higher, Can It Continue? - Tale of the Tape
Jul-21-15 08:30AMProgenics Pharmaceuticals Sets Second Quarter Financial Results Call for August 6 GlobeNewswire
Jul-09-15 10:18AMMoving Average Crossover Alert: Progenics Pharmaceuticals (PGNX) - Tale of the Tape
Progenics Pharmaceuticals, Inc. develops medicines for oncology in the United States and internationally. The company's primary clinical-stage product candidates include prostate specific membrane antigen (PSMA) antibody-drug conjugate, which has completed Phase II testing in chemotherapy-experienced patients and is ongoing second cohort in chemotherapy-nave patients for the treatment of prostate cancer; 1404, a radio-labeled small molecule that has completed Phase II testing, as well as acts as an imaging agent to diagnose and detect prostate cancer; and Azedra, a radiotherapeutic product candidate, which is in Phase IIb registrational trial under special protocol assessment for the treatment of pheochromocytoma and paraganglioma. It also offers Relistor-subcutaneous injection for the treatment of opioid induced constipation (OIC) in advanced-illness patients receiving palliative care when laxative therapy has not been sufficient; and for treatment of OIC inpatients with non-cancer pain. In addition, the company develops Relistor-oral that has completed Phase III testing for the treatment of OIC. Further, it develops MIP-1095, a PSMA-targeted small molecule radiopharmaceutical that is in clinical development stage for the treatment of prostate cancer. The company has license agreement with Salix Pharmaceuticals, Inc. for the development and commercialization of Relistor worldwide; and with Amgen Fremont, Inc. to use its XenoMouse technology for generating human antibodies to PSMA, as well as has collaboration agreement with Seattle Genetics, Inc. Progenics Pharmaceuticals, Inc. was founded in 1986 and is based in Tarrytown, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
ISRAEL ROBERT JExecutive Vice President, MediJun 11Option Exercise5.332,00010,66037,050Jun 15 09:32 AM
ISRAEL ROBERT JExecutive Vice President, MediJun 11Sale6.832,00013,66035,050Jun 15 09:32 AM
ISRAEL ROBERT JExecutive Vice President, MediMar 13Option Exercise5.353,00016,05038,050Mar 16 12:26 PM
ISRAEL ROBERT JExecutive Vice President, MediMar 13Sale7.003,00021,00035,050Mar 16 12:26 PM
ISRAEL ROBERT JExecutive Vice President, MediMar 11Option Exercise5.332,00010,66037,050Mar 13 09:26 AM
CompanyOncoGenex Pharmaceuticals, Inc.
Market Cap85.57MEPS (ttm)-0.93
P/E-EPS this Y33.20%
Forward P/E-EPS next Y-53.60%
PEG-EPS past 5Y-8.80%
P/S5.09EPS next 5Y-
P/B2.73EPS Q/Q66.10%
Dividend-Sales Q/Q-88.00%
Insider Own1.00%Inst Own37.40%
Insider Trans-6.16%Inst Trans-0.04%
Short Float4.43%EarningsAug 06/a
Analyst Recom1.50Target Price6.00
Avg Volume590.31K52W Range1.74 - 3.61
Jul-27-15 09:21AMOncoGenex Pharmaceuticals (OGXI) in Focus: Stock Jumps 5% - Tale of the Tape
Jul-14-15 07:53AMWilliam Blair Boosts OncoGenex Pharma Target To $6, Hikes Custirsen Probability To 70%
Jul-13-15 07:08AMONCOGENEX PHARMACEUTICALS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
Jul-13-15 07:00AMOncoGenex Announces Custirsen Phase 3 "ENSPIRIT" Trial Continues Following Completion of Final Futility Survival Analysis PR Newswire
Jul-13-15 07:00AMOncoGenex Announces Custirsen Phase 3 "ENSPIRIT" Trial Continues Following Completion of Final Futility Survival Analysis CNW Group
Jun-11-15 12:10PMOncoGenex Prostate Cancer Study Adds Co-primary Endpoint - Analyst Blog
Jun-10-15 12:00PMKB Home Earnings Call scheduled for 12:00 pm ET today
Jun-10-15 07:00AMFDA Agrees with OncoGenex' Phase 3 AFFINITY Protocol Amendment PR Newswire
OncoGenex Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapies that address treatment resistance in cancer patients. The company's product candidates include Custirsen that is in Phase III clinical development for the treatment in men with metastatic castrate-resistant prostate cancer, as well as in patients with non-small cell lung cancer; and Apatorsen, which is in two Phase I and seven randomized Phase II trials for the treatment of bladder, lung, pancreatic, and prostate cancers. It also develops OGX-225 that is in pre-clinical development for the treatment of solid tumors. The company has a collaboration agreement with Teva Pharmaceutical Industries Ltd. to develop and commercialize Custirsen. OncoGenex Pharmaceuticals, Inc. is headquartered in Bothell, Washington.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Cormack Scott DanielPresident and CEOJun 12Option Exercise0.009,3750116,513Jun 16 03:06 PM
JACOBS CINDYEVP, CMOJun 12Option Exercise0.005,000066,327Jun 16 03:08 PM
Cormack Scott DanielPresident and CEOJun 12Sale2.694,57112,296111,942Jun 16 03:06 PM
JACOBS CINDYEVP, CMOJun 12Sale2.691,4083,78864,919Jun 16 03:08 PM
Cormack Scott DanielPresident and CEOMay 20Sale1.887,54314,181107,138May 21 06:28 PM
CompanyBioSpecifics Technologies Corp.
Market Cap438.44MEPS (ttm)0.87
P/E74.77EPS this Y-13.20%
Forward P/E13.81EPS next Y149.21%
PEG3.40EPS past 5Y32.40%
P/S25.94EPS next 5Y22.00%
P/B13.01EPS Q/Q190.90%
Dividend-Sales Q/Q100.00%
Insider Own3.40%Inst Own57.20%
Insider Trans-32.45%Inst Trans0.18%
Short Float3.52%EarningsAug 06/a
Analyst Recom2.00Target Price76.00
Avg Volume58.27K52W Range25.77 - 65.96
Jul-20-15 05:42PMEdited Transcript of BSTC earnings conference call or presentation 12-May-15 1:00pm GMT
Jul-20-15 08:29AMBIOSPECIFICS TECHNOLOGIES CORP Files SEC form 8-K, Other Events, Financial Statements and Exhibits
Jul-20-15 08:00AMBioSpecifics Announces Approval of XIAFLEX® in Japan for the Treatment of Dupuytren's Contracture PR Newswire
Jul-16-15 07:05AMCoverage initiated on BioSpecifics Tech by MLV & Co
Jun-19-15 09:16AMBIOSPECIFICS TECHNOLOGIES CORP Files SEC form 8-K, Submission of Matters to a Vote of Security Holders
Jun-01-15 08:17AMBIOSPECIFICS TECHNOLOGIES CORP Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
May-26-15 08:30AMBioSpecifics Technologies Corp. to Present at the Jefferies 2015 Healthcare Conference PR Newswire
BioSpecifics Technologies Corp., a biopharmaceutical company, engages in the development of an injectable collagenase clostridium histolyticum for multiple indications in the United States. The company offers injectable collagenase for the treatment of Dupuytren's contracture and Peyronie's disease under the XIAFLEX brand in Canada, Australia, Brazil, and Mexico, as well as under XIAPEX brand name in Europe. It also provides injectable collagenase to treat frozen shoulder, cellulite, human lipoma, canine lipoma, and uterine fibroids. The company is also involved in the development of other clinical indications for which collagenase injection has been tested include keloids, hypertrophic scars, scarred tendons, glaucoma, herniated intervertebral discs, and as an adjunct to vitrectomy. It has a development and license agreement with Auxilium Pharmaceuticals, Inc. BioSpecifics Technologies Corp. was founded in 1957 and is headquartered in Lynbrook, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Gitman PaulDirectorJul 20Option Exercise13.608,692118,21160,517Jul 21 09:53 AM
Gitman PaulDirectorJul 20Sale53.008,692460,67651,825Jul 21 09:53 AM
Gitman PaulDirectorJun 23Option Exercise21.5436,308782,23988,133Jun 25 05:02 PM
Gitman PaulDirectorJun 23Sale51.7836,3081,879,91351,825Jun 25 05:02 PM
Gitman PaulDirectorMay 29Sale46.7615,000701,41051,825Jun 01 11:56 AM
CompanyPRA Health Sciences, Inc.
IndustryMedical Laboratories & Research
Market Cap2.43BEPS (ttm)-0.23
P/E-EPS this Y46.10%
Forward P/E20.64EPS next Y18.06%
PEG-EPS past 5Y-27.10%
P/S1.63EPS next 5Y18.00%
P/B3.75EPS Q/Q250.00%
Dividend-Sales Q/Q9.60%
Insider Own-Inst Own99.70%
Insider Trans-Inst Trans0.21%
Short Float2.30%EarningsJul 27/a
Analyst Recom1.80Target Price39.20
Avg Volume200.84K52W Range19.10 - 40.97
Jul-28-15 11:23AMPRA HEALTH SCIENCES, INC. Files SEC form 10-Q, Quarterly Report
Jul-28-15 09:55AMPRA Health Tops Q2 Earnings and Revenues, Raises EPS View - Analyst Blog
Jul-28-15 09:00AMPRA Health Sciences Inc Earnings Call scheduled for 9:00 am ET today
Jul-27-15 06:13PMPRA Health Sciences tops Street 2Q forecasts
Jul-27-15 05:51PM5:51 pm PRA Health Sciences beats by $0.06, reports revs in-line; raises FY15 EPS guidance above consensus, reaffirms FY15 revs guidance
Jul-27-15 05:47PMPRA Health Sciences, Inc. Reports Second Quarter 2015 Results and Provides Updated Guidance for 2015 GlobeNewswire
Jul-27-15 05:04PMPRA HEALTH SCIENCES, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and
Jul-27-15 07:07AMQ2 2015 PRA Health Sciences Inc Earnings Release - After Market Close
Jul-20-15 10:00AMPRA Health Sciences Launches New Initiative to Bolster Workforce GlobeNewswire
PRA Health Sciences, Inc., a contract research organization, provides various product development services for pharmaceutical and biotechnology companies worldwide. The company offers integrated services, such as data management, statistical analysis, clinical trial management, and regulatory and drug development consulting. Its services include a suite of product registration services, such as clinical trial management, project management, regulatory affairs, therapeutic expertise, clinical operations, data and programming, safety and risk management, biostatistics and medical writing, quality assurance, and late phase services. The company's services also comprise strategic solutions, including embedded, functional services provider, staff augmentation, and custom-built development solutions, as well as commercialization services; and early development services, including phase I through phase IIa clinical trials and bioanalytical laboratory services. It conducts clinical trials in the areas of pharmaceutical development, comprising oncology, central nervous system, inflammation, and infectious diseases. The company was formerly known as PRA Global Holdings, Inc. and changed its name to PRA Health Sciences, Inc. in July 2014. The company was founded in 1976 and is headquartered in Raleigh, North Carolina. PRA Health Sciences, Inc. is a subsidiary of KKR PRA Investors L.P.
CompanyICON Public Limited Company
IndustryMedical Laboratories & Research
Market Cap3.93BEPS (ttm)3.07
P/E21.16EPS this Y65.50%
Forward P/E15.86EPS next Y11.55%
PEG1.56EPS past 5Y11.70%
P/S2.55EPS next 5Y13.57%
P/B3.92EPS Q/Q57.90%
Dividend-Sales Q/Q11.00%
Insider Own8.22%Inst Own90.60%
Insider Trans0.00%Inst Trans0.40%
Short Float4.85%EarningsJul 28/b
Analyst Recom2.30Target Price74.18
Avg Volume527.14K52W Range46.75 - 72.40
Jul-28-15 09:00AMICON PLC Earnings Call scheduled for 9:00 am ET today
Jul-28-15 07:07AMQ2 2015 ICON PLC Earnings Release - Time Not Supplied
Jul-28-15 06:12AM6:12 am ICON plc beats by $0.06, misses on revs; raises FY15 EPS, lowers rev; adds $400 lmn to buyback
Jul-28-15 06:09AMIcon PLC beats 2Q profit forecasts
Jul-28-15 06:00AMICON Reports Second Quarter 2015 Business Wire
Jul-27-15 06:00AMICON Shareholders Vote in Favour of All Resolutions at its Annual General Meeting Business Wire
ICON Public Limited Company, a contract research organization, provides outsourced development services to the pharmaceutical, biotechnology, and medical device industries in Ireland, rest of Europe, the United States, and internationally. It develops, manages, and analyzes programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. The company also offers clinical trials management, biometric activities, consulting, imaging, contract staffing, informatics, and laboratory services. Its clinical development services include investigator recruitment, study monitoring and data collection, case report form preparation, statistical analysis, patient safety monitoring, risk-based monitoring, clinical data management, interactive response technologies, electronic patient reported outcomes, medical reporting, patient registries, outcomes research, health economics, market access and commercialization services, strategic analysis and data operations, bioanalysis, immunoassay development, pharmacokinetic and pharmacodynamic analysis, and study protocol preparation. The company's clinical development services also comprise regulatory consulting, product development planning, strategic consulting, pricing and market access consulting, strategic resourcing, electronic endpoint adjudication, sample analyses, safety testing, microbiology, custom flow cytometry, electronic transmission of test results, biomarker development, adaptive trial design and execution, medical device trials, and healthcare communication services. ICON Public Limited Company was founded in 1990 and is headquartered in Dublin, Ireland.
CompanyMicroStrategy Inc.
IndustryApplication Software
Market Cap2.02BEPS (ttm)2.77
P/E64.32EPS this Y-81.30%
Forward P/E24.40EPS next Y6.38%
PEG7.15EPS past 5Y-38.30%
P/S3.57EPS next 5Y9.00%
P/B5.79EPS Q/Q414.00%
Dividend-Sales Q/Q-10.20%
Insider Own22.43%Inst Own94.10%
Insider Trans-1.22%Inst Trans0.25%
Short Float1.81%EarningsJul 27/a
Analyst Recom2.20Target Price205.75
Avg Volume87.88K52W Range127.46 - 197.89
Jul-28-15 12:48PMWhy MicroStrategy Stock Popped Tuesday at Motley Fool
Jul-28-15 01:48AMEdited Transcript of MSTR earnings conference call or presentation 27-Jul-15 10:00pm GMT
Jul-27-15 06:00PMMicroStrategy Inc Earnings Call scheduled for 6:00 pm ET today
Jul-27-15 05:10PMMicroStrategy Cuts Costs, Boosts Profits and Cash Flow in Q2 at Motley Fool
Jul-27-15 04:46PMMICROSTRATEGY INC Files SEC form 8-K, Results of Operations and Financial Condition, Change in Directors or Principal
Jul-27-15 04:41PMMicroStrategy Jumps 7%: Q2 Revenue, EPS Beat; Names New CFO at
Jul-27-15 04:30PMMicroStrategy beats 2Q profit forecasts
MicroStrategy Incorporated designs, develops, markets, and sells enterprise-ready analytics, mobile, and security software platforms worldwide. It offers MicroStrategy Analytics Platform that delivers reports and dashboards, and enables users to conduct ad hoc analysis and share insights through mobile devices or the Web; and MicroStrategy Analytics Desktop to create data visualizations and dashboards. The company also provides MicroStrategy Mobile that enable organizations to build information-rich applications that deliver analytics combined with transactions, multimedia, and custom workflows to mobile devices; and MicroStrategy Usher, a mobile identity and security platform that primarily offers authentication, cybersecurity, access management, and resource authorization to businesses, universities, associations, governments, and other organizations. In addition, it offers MicroStrategy Secure Cloud that provides enterprise analytics and analytical databases, as well as extract, transform, load capabilities in an integrated environment. Further, the company provides technical support, consulting and advisory, and education services. It serves various industries, including retail, financial services and insurance, pharmaceutical and healthcare, manufacturing, consumer goods, government and public services, restaurants, and hospitality and leisure, as well as technology, media, and telecommunications. The company was founded in 1989 and is headquartered in Tysons Corner, Virginia.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Epstein Robert HDirectorJun 10Option Exercise121.431,731210,1951,731Jun 12 04:31 PM
Epstein Robert HDirectorJun 10Sale180.501,731312,4460Jun 12 04:31 PM
Epstein Robert HDirectorJun 05Option Exercise121.431,394169,2731,394Jun 09 04:33 PM
Epstein Robert HDirectorJun 05Sale180.501,394251,6170Jun 09 04:33 PM
Epstein Robert HDirectorMay 08Option Exercise121.433,125379,4693,325May 12 04:37 PM
TickerMAS [NYSE, S&P 500]
CompanyMasco Corporation
IndustryGeneral Building Materials
Market Cap8.05BEPS (ttm)2.36
P/E9.81EPS this Y189.20%
Forward P/E16.77EPS next Y22.76%
PEG0.60EPS past 5Y52.70%
P/S0.94EPS next 5Y16.30%
P/B10.34EPS Q/Q-14.30%
Dividend1.55%Sales Q/Q2.70%
Insider Own0.80%Inst Own92.80%
Insider Trans-19.57%Inst Trans1.03%
Short Float3.99%EarningsJul 28/b
Analyst Recom2.30Target Price26.88
Avg Volume4.20M52W Range17.24 - 24.84
Jul-28-15Upgrade Sun Trust Rbsn Humphrey Neutral → Buy
Jul-28-15Reiterated MKM Partners Neutral $25 → $26
Jul-28-15 03:07PMWhy Shares of Masco Corp Climbed 12% Today at Motley Fool
Jul-28-15 01:18PMMasco's Breakout Hints at More Upside to Come at TheStreet
Jul-28-15 10:43AMMasco Tops 2Q Profit Forecast
Jul-28-15 10:29AMMasco (MAS) Stock Jumping Following Earnings Release at TheStreet
Jul-28-15 09:30AMCramer: We have some bright spots
Jul-28-15 08:24AMMasco Corporation Beats on Earnings, Cabinet Sales Up Y/Y - Tale of the Tape
Jul-28-15 07:34AMMasco tops 2Q profit forecasts
Jul-28-15 07:16AMMASCO CORP /DE/ Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
Masco Corporation manufactures, distributes, and installs home improvement and building products worldwide. Its Cabinets and Related Products segment provides cabinetry for kitchen, bath, storage, home office, and home entertainment applications; and kitchen countertops, and integrated bathroom vanity and countertop solutions. The company's Plumbing Products segment offers faucets, showerheads, handheld showers, valves, bathing units, and toilets; acrylic tub and shower systems, bath and shower enclosure units, shower trays, and laundry tubs, as well as spas; and brass and copper plumbing system components, and other plumbing specialties. Its Decorative Architectural Products segment produces architectural coatings, including paints, primers, specialty paint products, stains, and waterproofing products; and cabinet, door, window, and other hardware products. The company's Other Specialty Products segment provides vinyl, fiberglass, and aluminum windows and patio doors; and manual and electric staple gun tackers, staples, and other fastening tools. Masco Corporation markets its products under the KRAFTMAID, MERILLAT, MOORES, QUALITY CABINETS, DELTA, PEERLESS, HANSGROHE, AXOR, BRIZO, BRASSTECH, BRISTAN, GINGER, HERITAGE, NEWPORT BRASS, PLUMB SHOP, HOT SPRING, CALDERA, FREEFLOW, MIROLIN, BRASSCRAFT, COBRA, MASTER PLUMBER, BEHRPRO, BEHR, KILZ, LIBERTY, BRAINERD, FRANKLIN BRASS, DECOR BATHWARE, MILGARD, GRIFFIN, PREMIER, and DURAFLEX brands. The company sells its products to home improvement and new home construction markets through mass merchandisers, hardware stores, home centers, homebuilders, distributors, and other outlets, as well as directly to the consumers. The company was founded in 1929 and is headquartered in Taylor, Michigan.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Volas GeraldGr. Pres. - N.A. Divrs. Bus.Jun 10Option Exercise16.17235,7503,811,678344,008Jun 11 12:58 PM
Volas GeraldGr. Pres. - N.A. Divrs. Bus.Jun 10Sale27.7453,1161,473,640229,654Jun 11 12:58 PM
O'Reagan Richard A.Gr. Pres. - Global Plmb.May 08Sale26.415,800153,19274,734May 12 01:51 PM
Allman Keith J.President and CEOMar 13Option Exercise14.98159,2202,385,027354,695Mar 16 04:48 PM
Allman Keith J.President and CEOMar 13Sale26.4237,001977,545301,700Mar 16 04:48 PM
TickerRAI [NYSE, S&P 500]
CompanyReynolds American Inc.
Market Cap50.42BEPS (ttm)2.80
P/E28.28EPS this Y-14.00%
Forward P/E17.67EPS next Y14.63%
PEG2.24EPS past 5Y10.50%
P/S5.87EPS next 5Y12.60%
P/B9.32EPS Q/Q15.90%
Dividend3.38%Sales Q/Q6.30%
Insider Own0.10%Inst Own40.20%
Insider Trans-17.38%Inst Trans0.59%
Short Float2.54%EarningsJul 28/b
Analyst Recom1.90Target Price85.38
Avg Volume3.31M52W Range53.05 - 80.56
Jul-28-15 12:03PMCan Reynolds Make Lorilland Grow in the Tobacco Industry? at Bloomberg
Jul-28-15 10:49AMRAI CEO: Very excited about growth prospects
Jul-28-15 10:06AMReynolds American Rises After Increasing Annual Profit Forecast at Bloomberg
Jul-28-15 09:25AMReynolds American (RAI) Stock Up on Earnings Beat, Guidance Hike at TheStreet
Jul-28-15 08:56AMReynolds American Lifts Earnings Outlook at The Wall Street Journal
Jul-28-15 08:36AMEarly movers: F, PFE, MRK, DD, WYN, DHI & more at CNBC
Jul-28-15 08:14AMReynolds Q2 Earnings Beat, Revenues Miss; Announces Dividend Hike - Tale of the Tape
Jul-28-15 08:05AMReynolds American beats 2Q profit forecasts
Jul-28-15 07:53AMREYNOLDS AMERICAN INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exh
Reynolds American Inc., through its subsidiaries, manufactures and sells cigarettes and other tobacco products in the United States. It operates through RJR Tobacco, American Snuff, and Santa Fe segments. The RJR Tobacco segment offers cigarettes under the brand names of CAMEL, PALL MALL, WINSTON, KOOL, DORAL, SALEM, MISTY, and CAPRI; and CAMEL Snus, a smoke-free tobacco product, as well as manages various licensed brands, including DUNHILL and STATE EXPRESS 555. The American Snuff segment provides smokeless tobacco products, such as moist snuff under GRIZZLY and KODIAK brand names. The Santa Fe segment offers cigarettes and other tobacco products under the NATURAL AMERICAN SPIRIT brand name. The company also provides electronic cigarettes; manufactures digital vapor cigarettes under the VUSE brand name; and markets and distributes nicotine replacement therapy products under ZONNIC brand name in Sweden. It distributes its products primarily through direct wholesale deliveries from a local distribution center and public warehouses. Reynolds American Inc. was founded in 2004 and is headquartered in Winston-Salem, North Carolina.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
CALDWELL LISA JEVP & Chief HR OfficerMar 11Sale69.9913,518946,15234,847Mar 12 10:22 AM
Dunham Robert H.EVP - Public AffairsMar 11Sale69.9912,539877,65516,000Mar 12 10:22 AM
FOLAN MCDARASVP, Deputy GC & SecretaryMar 11Sale69.998,899622,86513,308Mar 12 10:22 AM
Gentry Jeffery SEVP-Operations & CSO of RJRTCMar 11Sale70.0015,5121,085,76235,028Mar 12 10:23 AM
Auger Michael P.EVP - Trade Marketing of RJRTMar 11Sale70.004,870340,87716,716Mar 12 10:21 AM
CompanyCadence Design Systems Inc.
IndustryApplication Software
Market Cap5.55BEPS (ttm)0.52
P/E36.48EPS this Y-7.10%
Forward P/E16.71EPS next Y11.38%
PEG3.65EPS past 5Y23.70%
P/S3.44EPS next 5Y10.00%
P/B3.96EPS Q/Q9.10%
Dividend-Sales Q/Q8.70%
Insider Own0.50%Inst Own-
Insider Trans-58.93%Inst Trans1.24%
Short Float17.50%EarningsJul 27/a
Analyst Recom2.10Target Price21.90
Avg Volume3.72M52W Range15.50 - 20.51
Jul-28-15 01:36PMStocks In Rebound Mode; Icon, Cadence Break Out at Investor's Business Daily
Jul-28-15 12:20PMWhy Cadence Design Systems Shares Soared 11% at Motley Fool
Jul-28-15 10:50AMEdited Transcript of CDNS earnings conference call or presentation 27-Jul-15 9:00pm GMT
Jul-28-15 10:10AMCadence Design (CDNS) Stock Gains on Earnings Beat at TheStreet
Jul-27-15 05:23PMMonday's After-Hours Movers: Baidu, Cadence Design Systems, Amkor Tech And More
Jul-27-15 05:18PMCadence beats 2Q profit forecasts AP
Jul-27-15 04:21PMCadence Design Rising: Q2 EPS Beats, Sets New $1.2B Buyback Plan at
Jul-27-15 04:17PMCadence Design Systems (CDNS) Stock Gains in After-Hours Trading on Earnings Beat at TheStreet
Jul-27-15 04:11PMCADENCE DESIGN SYSTEMS INC Files SEC form 8-K, Results of Operations and Financial Condition
Cadence Design Systems, Inc. develops, sells, leases, and licenses electronic design automation (EDA) software, emulation and prototyping hardware, verification intellectual property (VIP), and design intellectual property (design IP) for semiconductor and electronics systems industries worldwide. It offers functional verification products, including logic verification software that enables customers to coordinate verification activities across multiple teams and various specialists for verification planning and closure; and system design and verification products for hardware-software verification, as well as for system power exploration, analysis, and optimization. The company also provides digital integrated circuits (ICs) design products, such as logic design products for chip planning, design, verification, and test technologies and services; physical implementation products for use in place and route, signal integrity, optimization, and double patterning preparation; and signoff products to signoff the design as ready for manufacture by a silicon foundry, as well as design for manufacturing products for use in the product development process. In addition, it offers custom IC design and verification products to create schematic and physical representations of circuits down to the transistor level for analog, mixed-signal, custom digital, memory, and RF designs; and system interconnect design products to develop printed circuit boards and IC packages. Further, the company provides design IP products consisting of pre-verified and customizable functional blocks to integrate into customer's SoCs; and VIP and memory models for use in system-level verification to model correct behavior of full systems interacting with their environments. Additionally, it offers engineering, methodology, education, and hosted design solutions, as well as technical support and maintenance services. The company was founded in 1988 and is headquartered in San Jose, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Huang Charlie X.Executive Vice PresidentJul 17Option Exercise11.2045,000504,000258,586Jul 17 06:56 PM
Huang Charlie X.Executive Vice PresidentJul 17Sale19.4745,000876,150213,586Jul 17 06:56 PM
Huang Charlie X.Executive Vice PresidentJun 18Option Exercise11.2045,000504,000258,586Jun 22 06:54 PM
Lund MartinSr. Vice PresidentJun 18Sale20.1625,000503,910117,249Jun 22 06:17 PM
Huang Charlie X.Executive Vice PresidentJun 18Sale20.1645,000907,362213,586Jun 22 06:54 PM
1 2 3 4 5 6 7 next